DFV Deutsche Familienversicherung AG

  • WKN: A2NBVD
  • ISIN: DE000A2NBVD5
  • Land: Deutschland

Analyst Coverage

Research Analyst Datum Empfehlung Target

Bankhaus Metzler

Jochen Schmitt Nov 19, 2021 Buy 17.00 EUR

Berenberg

Gerhard Orgonas Aug 16, 2021 Buy 23.00 EUR

Hauck & Aufhäuser

Christian Salis Nov 12, 2021 Buy 22.00 EUR

Keefe, Bruyette & Woods

René Locher Nov 11, 2021 Buy 24.00 EUR

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021